Form 4: BioAffinity Technologies Executive Chairman Steven Girgenti Reports Share Transactions

Steven Girgenti, Executive Chairman of bioAffinity Technologies, reports acquisition and disposal of common stock, including a grant of restricted shares.

Summary

• Steven Girgenti, the Executive Chairman of bioAffinity Technologies, Inc., filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On July 1, 2024, Girgenti acquired 33,784 shares of common stock through a grant of restricted shares.
• These shares vest pro rata on a monthly basis over 12 months, starting August 1, 2024.
• On the same day, Girgenti disposed of 8,955 shares held indirectly through the Cranye Girgenti Testamentary Trust.
• Following these transactions, Girgenti directly owns 1,065,248 shares of common stock.
• Girgenti disclaims beneficial ownership of the shares held by the Trust except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral. It simply reports transactions without expressing any particular opinion or outlook.

Positives

• The grant of restricted shares to the Executive Chairman could be seen as an incentive to align his interests with the company's long-term success.

Negatives

• The disposal of shares held by the Cranye Girgenti Testamentary Trust could be interpreted negatively, although the reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Risks

• The vesting schedule of the restricted shares could influence the Executive Chairman's decisions over the next 12 months.
• Changes in ownership, even indirect ones, can sometimes create uncertainty among investors.

Future Outlook

The vesting of restricted shares over the next 12 months suggests a continued alignment of the Executive Chairman's interests with the company's performance.

Management Comments

• The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Monitoring insider transactions is a common practice in financial analysis.
• Comparing the size and frequency of insider transactions to those of peer companies can provide insights into the relative attractiveness of an investment.

Stakeholder Impact

• Shareholders may be interested in the Executive Chairman's stock transactions as an indicator of his confidence in the company.
• The vesting of restricted shares could incentivize the Executive Chairman to focus on long-term value creation.

Key Dates

Keywords

bioAffinity Technologies, Steven Girgenti, Form 4, Beneficial Ownership, Restricted Shares, Stock Transaction, Cranye Girgenti Testamentary Trust